NewLimit Raises $435 million Series B
Longevity startup NewLimit raised $435M in Series B financing led by investors — first, with participation from investors — first, a $130 million Series B round in May 2025, followed by another $45 million in October. Longevity startup NewLimit is a South San Francisco-based Digital Health company focused on launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding. The new capital is framed around launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
What it does
Longevity startup NewLimit is a South San Francisco-based Digital Health company focused on launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding. The business sits in Digital Health, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
$435 million. Management framed the new capital around launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
Trend impact
Longevity startup NewLimit aims to displace fragmented care delivery and legacy clinician workflow software with AI-enabled healthcare tooling. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- June 2, 2026 · Series B · $435 million · investors — first, a $130 million Series B round in May 2025, followed by another $45 million in October
Products & services
- Digital Health workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for digital health teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round